Additional research highlights integration of BluePrint molecular subtyping and Read More
Multivariate analyses reveal that pathologic complete response is associated Read More
Poster presentations highlight the prognostic value of MammaPrint + Read More
Multicenter study of over 1000 females with breast cancer, Read More
Agendia Announces NCCN Guideline Update Recognizing MammaPrint to Guide Read More
Four additional poster presentations from the ongoing real-world FLEX Read More
IRVINE, CALIF., U.S., and AMSTERDAM, NETHERLANDS – August 12, Read More
FLEX Study Highlights Clinical Utility of MammaPrint® and BluePrint® Read More
FLEX Study reaches milestone of 20,000 enrolled patients, providing Read More
Real-world analysis shows BluePrint® identifies chemotherapy-sensitive Basal-type tumors among Read More
Contact
For the US, Puerto Rico, Canada
and South America
Agendia Inc. USA, 22 Morgan, Irvine, CA 92618
(888) 321-2732
customercare@agendia.com
Fax: (844) 711-9132
For outside the Americas
Agendia NV, Radarweg 60, 1043 NT Amsterdam, The Netherlands
+31 (0)20 462 1510
customerservice@agendia.com
©2026 Agendia. All rights reserved. MammaPrint and Blueprint are registered trademarks of Agendia, Inc.
CHIEF COMPLIANCE OFFICER
Stephanie has worked in compliance since 2005 and has extensive experience developing and managing programs to support compliance with global, federal, and state laws and regulations in the healthcare and biotech industries. Prior to joining Agendia, Stephanie spent a significant portion of her career serving as a compliance officer in laboratories, such as HealthTrackRx, NeoGenomics, and Myriad Genetics, and held compliance leadership roles in medical device, pharma, and large health systems.
Stephanie graduated Summa Cum Laude with a B.S. in Healthcare Administration from Northern Illinois University and is Certified in Healthcare Compliance (CHC), Data Privacy (CHP), Research Compliance (CHRC), and is a Certified Internal Auditor (CIA).
